Department of Clinical Sciences, Institute of Tropical Medicine (ITM), Unit of Tropical Laboratory Medicine, Nationalestraat 155, B 2000 Antwerp, Belgium.
Malar J. 2011 Feb 13;10:39. doi: 10.1186/1475-2875-10-39.
The present study assessed malaria RDT kits for adequate and correct packaging, design and labelling of boxes and components. Information inserts were studied for readability and accuracy of information.
Criteria for packaging, design, labelling and information were compiled from Directive 98/79 of the European Community (EC), relevant World Health Organization (WHO) documents and studies on end-users' performance of RDTs. Typography and readability level (Flesch-Kincaid grade level) were assessed.
Forty-two RDT kits from 22 manufacturers were assessed, 35 of which had evidence of good manufacturing practice according to available information (i.e. CE-label affixed or inclusion in the WHO list of ISO13485:2003 certified manufacturers). Shortcomings in devices were (i) insufficient place for writing sample identification (n=40) and (ii) ambiguous labelling of the reading window (n=6). Buffer vial labels were lacking essential information (n=24) or were of poor quality (n=16). Information inserts had elevated readability levels (median Flesch Kincaid grade 8.9, range 7.1-12.9) and user-unfriendly typography (median font size 8, range 5-10). Inadequacies included (i) no referral to biosafety (n=18), (ii) critical differences between depicted and real devices (n=8), (iii) figures with unrealistic colours (n=4), (iv) incomplete information about RDT line interpretations (n=31) and no data on test characteristics (n=8). Other problems included (i) kit names that referred to Plasmodium vivax although targeting a pan-species Plasmodium antigen (n=4), (ii) not stating the identity of the pan-species antigen (n=2) and (iii) slight but numerous differences in names displayed on boxes, device packages and information inserts. Three CE labelled RDT kits produced outside the EC had no authorized representative affixed and the shape and relative dimensions of the CE symbol affixed did not comply with the Directive 98/79/EC. Overall, RDTs with evidence of GMP scored better compared to those without but inadequacies were observed in both groups.
Overall, malaria RDTs showed shortcomings in quality of construction, design and labelling of boxes, device packages, devices and buffers. Information inserts were difficult to read and lacked relevant information.
本研究评估了疟疾 RDT 试剂盒的包装、盒体和组件设计以及标签是否充分和正确。还研究了信息插页的可读性和信息准确性。
根据欧盟指令 98/79 号、世界卫生组织(世卫组织)相关文件以及关于终端用户使用 RDT 情况的研究,拟定了包装、设计、标签和信息标准。评估了印刷字体和易读性(Flesch-Kincaid 阅读水平等级)。
评估了来自 22 家制造商的 42 个 RDT 试剂盒,其中 35 个根据现有信息(即贴有 CE 标签或列入世卫组织 ISO13485:2003 认证制造商名单)显示符合良好生产规范。设备存在的缺陷包括:(i)样本识别标记空间不足(n=40),(ii)检测窗标签标注不明确(n=6)。缓冲液小瓶标签缺少必要信息(n=24)或质量差(n=16)。信息插页的易读性水平较高(中位数 Flesch Kincaid 阅读水平 8.9,范围 7.1-12.9),排版不便于用户使用(中位数字体大小 8,范围 5-10)。不足之处包括:(i)未提及生物安全(n=18),(ii)设备实际情况与图示之间存在差异(n=8),(iii)图像颜色不现实(n=4),(iv)关于 RDT 线解释的信息不完整(n=31),检测特征数据缺失(n=8)。其他问题包括:(i)试剂盒名称指的是间日疟原虫,但针对的是泛物种疟原虫抗原(n=4),(ii)未说明泛物种抗原的身份(n=2),(iii)盒体、设备包装和信息插页上显示的名称略有不同,但数量众多。3 个欧盟境外生产的贴有 CE 标签的 RDT 试剂盒未贴有授权代表标签,CE 符号的形状和相对尺寸不符合指令 98/79/EC。总体而言,符合 GMP 的 RDT 与不符合 GMP 的相比,在包装、盒体、设备包装、设备和缓冲液质量方面表现较好,但两组均存在不足之处。
总体而言,疟疾 RDT 在结构质量、盒体和组件设计以及标签方面存在缺陷,设备和缓冲液也存在问题。信息插页难以阅读,且缺乏相关信息。